@FierceBiotech: ICYMI yesterday: J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex. Report | Follow @FierceBiotech
@JohnCFierce: Catalent stops production at French plant, brings in law enforcement after it twice detects tampering. FiercePharma story | Follow @JohnCFierce
@DamianFierce: Fun reminder of pharma's insane margins: $NVS has a Map My Run ad for a multiple sclerosis drug. Item | Follow @DamianFierce
> Sweden's Medivir is scrapping its ADAM8 inhibitor program for pancreatic cancer. And its licensing agreement with Cancer Research Technology is being thrown out alongside the program. Release
> Ambrx, 6 months removed from being acquired by a group of Chinese drugmakers, has recruited Amgen ($AMGN) veteran Yong-Jiang Hei to serve as its chief medical officer. More
> The U.K.'s Cell Therapy Catapult has begun construction of its cell and gene therapy manufacturing center. Release
Medical Device News
@FierceMedDev: Crime syndicates are hacking devices to steal private medical information for profit. ICYMI last week | Follow @FierceMedDev
@EmilyWFierce: FDA calling for more regulation of lab-developed tests prior to congressional hearing today. More from the WSJ | Follow @EmilyWFierce
> SI-Bone gets $39M+ in debt to market joint fusion implant system. Story
> FDA approves, Medtronic launches the first remote monitoring pacemaker app. Report
> Diagnostics companies jump into rapidly growing market for point-of-care superbug tests. Article
Pharma News
@FiercePharma: Indonesia's Kalbe and South Korea's Genexine link up for biomedical work. FiercePharmaAsia report | Follow @FiercePharma
@EricPFierce: There are lots of changes going on among generics producers but here are the top players. Feature | Follow @EricPFierce
> J&J undercuts Celgene's Pomalyst with $135K-per-year Darzalex price. Report
> Can Valeant win without big price hikes? Early Addyi scripts aren't a good sign. More
> U.S. lawmakers step up drug-pricing probes, add Valeant pharmacy to their target list. Article
Pharma Manufacturing News
> Top Novartis exec in India says two plants warned by FDA completing remediation. Item
> Baxter Singapore plant gets FDA OK to produce Advate hemophilia product. More
> Valeant adds recall to long list of problems. Article
> Regulator halts Catalent production at French plant where product sabotage suspected. Report
> Four Roche plants go up for sale in move to more high-potency, targeted drugs. Story
Drug Delivery News
> NC State team: Gold nanoparticles can control the shape of DNA, RNA. Report
> Avedro bags $32M in financing to expand use of its drug delivering ophthalmology platform. More
> Egalet announces patent for its abuse-deterrence platform. Item
> Swiss scientists take a look inside 'cubosomes' for drug delivery potential. Story
> RetroSense bags $6M in funding for its viral vector gene therapy candidate for a rare eye condition. Article
Pharma Asia News
> Lee's Pharma affiliate licenses Tragara's TG02 oncology treatment for much of Asia. Story
> Indian drugmakers eye Japanese market for acquisitions. Report
> India looks to push development of biotech startups. More
> HK-based Chi-Med takes another regulatory step to Nasdaq listing. Article
> Australia's Mesoblast formally lists on Nasdaq. Item